Evaluation of HER2/Neu Receptors and Its Comparison with Pathologic Parameters in Rural Breast Cancer Patients in Eastern India

Nazir Abdul Wasim; Arijit Majumdar; Karabi Konar; Prasenjit Sadhukhan; Debanjan Bhattacharjee

doi:10.21276/apalm.3329

Authors

Nazir Abdul Wasim Department of Pathology, Sarat Chandra Chattopadhyay Government Medical College & Hospital, Howrah, West Bengal, India
Arijit Majumdar Department of Pathology, Deben Mahata Government Medical College & Hospital, Hatuara, Purulia, West Bengal, India
Karabi Konar Department of Pathology, Malda Medical College & Hospital, Malda, West Bengal, India
Prasenjit Sadhukhan Department of Paediatrics, Midnapore Medical College & Hospital, Paschim Medinipur, West Bengal, India
Debanjan Bhattacharjee Department of Pathology, Midnapore Medical College & Hospital, Paschim Medinipur, West Bengal, India

DOI:

https://doi.org/10.21276/apalm.3329

Keywords:

Breast Carcinoma, Histological Subtypes, HER-2/neu Expression, Eastern India

Abstract

Background: The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of Her-2/neu has been associated with a worse outcome in patients with breast cancer. Hormone receptor expression has been reported to be low in breast cancer patients from developing countries, including India. The pattern of receptor expression in rural areas is not well studied.

Materials and Methods: Immunohistochemistry was used for the evaluation of HER-2/neu expression in the mastectomy specimens. Tumor size from the mastectomy specimen was recorded, and the number of lymph nodes was noted. Tissue processing and staining with hematoxylin and eosin were done. Post-mastectomy grading of the malignant breast lesion was done according to the Scarff-Bloom-Richardson (SBR) grading system in hematoxylin and eosin stained slides.

Results: Among the histopathological types of the tumors, IDC NOS constituted 40 cases (86.9%), invasive lobular carcinoma constituted 2 cases (4.3%), medullary carcinoma 2 cases (4.3%), invasive papillary carcinoma and mucinous carcinoma 1 case each (2.2%). The number of HER-2/neu positive cases was 28 (60.9%) and 18 cases were found negative (39.1%). The total number of ER positive and negative cases were 21 (45.7%) and 25 (54.3%), respectively. The total number of PR positive cases was 18 (39.1%) and that of negative cases was 28 (60.9%).

Conclusion: HER-2/neu overexpression is significantly associated with clinicopathological parameters such as younger age group, increased tumor size, higher tumor grades, axillary lymph node metastases, skin involvement, and higher clinical staging.

References

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, PiÃ±eros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5.

Park JE. Cancer. In: Park JE, editor. Parkâ€™s Textbook of Preventive and Social Medicine. Banarsidas Bhanot Publishers; 2019. p. 433-434.

GLOBOCAN. GLOBOCAN, The Global Cancer Observatory, Fact Sheet, India. [June; 2023]. 2020. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data [Accessed 2023 Sep 11].

Rashed MM, Ragab NM, Galal MK. The association of HER-2/NEU over-expression in relation to P53 nuclear accumulation, hormonal receptor status and common clinico-pathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. Eur J Gen Med. 2007;4(2):73-9.

Mohamad IB, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Med J Dr D.Y. Patil Univ. 2016 Nov-Dec;9(6):674-9.

Coussens L, Yang-Feng TL, Lioa YC, Chen Eea. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-9.

Anwar N, Mokhtar N, Mourad M, et al. cerbB2 and its relation to lymph node positivity: Short term follow-up in Egyptian cancer patients. CMB. 1994;1:325-9.

Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359-77.

Nottingham or Bloom-Richardson (BR) Score/Grade. Available from: https://staging.seer.cancer.gov/cs/input/02.05.50/breast/ssf7/?version=/tnm/home/1.7/ [Accessed 2023 Sep 11].

Che Y, Ren F, Zhang X, Cui L, Wu H, Zhao Z. Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning. Diagnostics (Basel). 2023 Jan 10;13(2):263.

Walker RA. Use and assessment of diagnostic and predictive markers in breast pathology. Curr Diagn Pathol. 2007;13:126-34.

van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239-45.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan. Breast Cancer Res. 2004;10:186/738.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res. 2006;12(2):83-6.

Looi LM, Cheah PL. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast correlates to high histologic grade and loss of estrogen receptor protein. Malays J Pathol. 1998;20:19-23.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005;11:278-80.

Al-Dujaily ES. Pathological Study of Breast Cancer By Application of Epidermal Growth Factor Receptor Type II(HER-2/neu) (Immunohistochemical study) [thesis]. 2008.

Saleh F, Abdeen S. Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog. 2007 Sep 24;6:12.

Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010 Sep;132:287-94.

Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol. 2001 Feb 1;19(3):645-56.

Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001 Sep;10(3):139-52.

Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbas F. Significance of HER-2/neu oncoprotein overexpression on node positive invasive breast cancer. J Coll Phys Surg Pak. 2002;12:534-7.

Descotes F, Adessi GL. Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res. 1993;13:119-24.

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98:547-53.

Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res. 2005;7:1200.

Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A, et al. Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res. 2003;9(4):226-31.

Aziz SA, Pervez S, Khan S, et al. Significance of immunohistochemical c-erbB2 product localization pattern for prognosis in human breast cancer. Pathol Oncol Res. 2001;7.

Marc J, Johannes LP, Wolter JM, Van DV, et al. Neuâ€“protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239-45.